GNBT: Reports 'Positive' Bird-Flu Meeting
Generex Biotechnology Corp. (GNBT) said it clarified the development path and timetable for its Antigen Express unit's bird-flu vaccine after meeting with regulators, clearing the way for the company to file an investigational new drug application ahead of clinical trials. In a press release Monday, Generex, a Toronto pharmaceutical company, said Antigen Express representatives had a "positive" pre-investigational new drug application meeting with regulators from the FDA.
The drug is a vaccine designed to protect against the H5N1 strain of avian influenza. The meeting was requested by Antigen Express, which requires a new drug application so the company can test the drug on humans.
&ind_volume=ON&secu=InfoSharer%3A%3AStock%3DHASH(0x9a60a68)&a=922012&zeitraum=5&von=0&banner_ref=HASH(0x9189fc4)&bname=&req_host=www.ariva.de&b=0&zeitvon=&bis=1140557413&ind_adhoc=&ind_gd38=ON)
Generex Biotechnology Corp. (GNBT) said it clarified the development path and timetable for its Antigen Express unit's bird-flu vaccine after meeting with regulators, clearing the way for the company to file an investigational new drug application ahead of clinical trials. In a press release Monday, Generex, a Toronto pharmaceutical company, said Antigen Express representatives had a "positive" pre-investigational new drug application meeting with regulators from the FDA.
The drug is a vaccine designed to protect against the H5N1 strain of avian influenza. The meeting was requested by Antigen Express, which requires a new drug application so the company can test the drug on humans.
